Release Date: June 30, 2025
Expiration Date: June 30, 2026
Activity Overview
The PER Postgame™ is an online, on-demand video program that brings together renowned experts in the treatment of IgA nephropathy (IgAN). In this educational program, these experts review the screening and diagnosis of IgAN utilizing a multidisciplinary approach and delve into current and emerging therapies that have been developed based on advancements in knowledge regarding the pathogenesis of IgAN. A case study will be presented, allowing the experts to share their perspectives on treatment and best practices.
Target Audience
This educational activity is directed toward nephrology nurses. Nephrologists and other HCPs involved in the management of patients with IgAN will also find it useful.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss the most recent updates on the pathophysiology and pathogenesis of IgAN
- Apply strategies to evaluate patients with IgAN
- Analyze recent efficacy and safety trial data on new and emerging treatments for IgAN
- Summarize guideline recommendations for the individualized treatment of patients with IgAN
Editor's Note:
On August 27, 2025, the FDA modified the Risk Evaluation and Mitigation Strategies (REMS) program for the use of sparsentan in the treatment of IgA nephropathy due to the risk of hepatotoxicity. The update reduces the frequency of liver function monitoring to every 3 months from the onset of treatment with sparsentan and removes the embryo-fetal toxicity (EFT) monitoring requirement from the REMS.
Gerald Bernard Appel, MD
Professor of Medicine – Columbia U. Med. Ctr.
Co-Director Glomerular Kidney Center
New York, NY
Disclosures: Consultant: Glaxo, Aurinia, Apellis, Novartis, Travere: Speaker’s Bureau; Glaxo, Aurinia, Calliditas: Grant and Research Support; All through Columbia U. – Calliditas, Novartis, Apellis: Other; UpToDate Editor and contributor to IgAN section
Ellie Kelepouris, MD, FACP, FAHA
Professor of Clinical Medicine
Vice Chair for Clinical Affairs
Division of Nephrology
University of Pennsylvania
Philadelphia, PA
Disclosures: Consultant: Bayer; Advisory Board: CSL Vifor, Vera, Travere
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource, LLC, (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
